

BANDARAM PHARMA PACKTECH LIMITED

(Formerly known as Shiva Medicare Limited)

CIN: L93090KA1993PLC159827

To,

Date: 30.05.2022

BSE Limited

P.J. Towers, Dalal Street

Mumbai- 400001

(BSE Scrip Code: 524602)

Dear Sir/ Madam,

Sub: Outcome of Board Meeting held on 30.05.2022

Unit: Bandaram Pharma Packtech Limited (formerly known as Shiva Medicare Limited)

With reference to the subject cited, this is to inform the exchanges that the Board of Directors of **Bandaram Pharma Packtech Limited (formerly known as Shiva Medicare Limited)** at its meeting held on Monday, the 30th day of May 2022 at 4.00 P.M. at the registered office of the Company situated at 601, 5th Floor, Oxford Towers, Opp to Leela Palace Hotel, Old Airport Road, Kodihalli Bangalore - 560008, Karnataka, approved the following items of business:

1. Audited Financial Results for the Quarter and Financial Year ended 31st March 2022. (Enclosed as Annexure).
2. Audit Report for the Quarter and Financial Year ended 31st March 2022. (Enclosed as Annexure).

The meeting concluded at 4:30 P.M.

This is for the information and records of the Exchanges, please.

Thanking you.

For Bandaram Pharma Packtech Limited

(Formerly known as Shiva Medicare Limited)



B. Munirathnam Reddy

Managing Director

DIN: 09487708


BANDARAM PHARMA PACKTECH LIMITED (Formerly Known as Shiva Medicare Limited)

CIN: L93090KA1993PLC159827

Statement of Audited Results for the Quarter Ended and Six Months Ended 31.03.2022 (Amount in lakhs)

S.No.	Particulars	For the Quarter ended			Year Ended	
		31.3.2022 (Audited)	31.12.2021 (Audited)	31.03.2021 (Audited)	31.03.2022 (Audited)	31.03.2021 (Audited)
I.	Revenue from Operations	-	-	-	-	-
II.	Other Income	-	-	-	-	-
III.	Total income (I+II)	-	-	-	-	-
IV.	Expenses					
	(a) Cost of Materials consumed	-	-	-	-	-
	(b) Purchase of stock-in-trade	-	-	-	-	-
	(c) Changes in inventories of finished goods,	-	-	-	-	-
	(d) Employee benefits expense	-	-	-	-	-
	(e) Finance Cost	0.01	-	-	0.01	-
	(f) Depreciation and amortisation expense	-	-	-	-	-
	(h) Other expenses	1.00	-	-	1.00	-
	Total Expenses	1.01	-	-	1.01	-
V.	Profit / (Loss) before and exceptional items and Tax (III-IV)	(1.01)	-	-	(1.01)	-
VI.	Exceptional Items	-	-	-	-	-
VII.	Profit / (Loss) from before tax (V-VI)	(1.01)	-	-	(1.01)	-
VIII.	Tax expense					
	Current Tax	-	-	-	-	-
	Deferred Tax	-	-	-	-	-
IX.	Net Profit / (Loss) for the period from Continuing operations (VII-VIII)	(1.01)	-	-	(1.01)	-
X.	Profit/ (Loss) from discontinuing operations	-	-	-	-	-
XI.	Tax Expense of discontinuing operations	-	-	-	-	-
XII.	Profit/ (Loss) from discontinuing operations after tax	-	-	-	-	-
XIII.	Profit/(loss) for the Period (IX+XII)	(1.01)	-	-	(1.01)	-
XIV.	Other Comprehensive Incomes					
A.	(i) Items that will not be recycled to profit or loss	-	-	-	-	-
	(a) Others (gratuity and leave encashment excess provision reversal)	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-
B.	(i) Items that may be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax on items that may be reclassified to profit or loss	-	-	-	-	-
	Total Comprehensive Income	-	-	-	-	-
XV.	Total Comprehensive Income for the	(1.01)	-	-	(1.01)	-
XVI.	Earnings Per Equity Share of face value of Rs.10/- each)(for Countinuing					
	1) Basic	(0.00)	-	-	(0.00)	-
	2) Diluted	(0.00)	-	-	(0.00)	-
XVII.	Earnings Per Equity Share of face value of Rs.10/- each) (for Discountinuing					
	1) Basic	(0.00)	-	-	(0.00)	-
	2) Diluted	(0.00)	-	-	(0.00)	-
XVIII.	Earnings Per Equity Share of face value of Rs.10/- each) (for Continued and Discountinuing opertions):					
	1) Basic	(0.00)	-	-	(0.00)	-
	2) Diluted	(0.00)	-	-	(0.00)	-
XIX.	Paid-up equity share capital (Face Value of Rs. 10/- per share)	300.00	227.70	227.70	300.00	227.70

For BANDARAM PHARMA PACKTECH LIMITED




Managing Director

Notes:

1. The Company was under CIRP and previous Board was suspended. New Board is appointed on 07-03-2022 as per the order dated 07-02-2022, issued by the NCLT, Hyderabad.
2. The Company name was changed from M/s. Shiva Medicare Ltd., to M/s. Bandaram Pharma Packtech Ltd., w.e.f. 16-03-2022.
3. In pursuance with Regulation 33 of SEBI (LODR) Regulations, 2015 and Schedule III of the Companies Act, 2013, the above Financial Results have been prepared. The same is reviewed by the Statutory Auditors of Company and recommended by the Audit Committee and subsequently approved by the Board of Directors of Company at their meeting held on 20-05-2022.
4. The Financial Statements have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS, prescribed under Section 133 of the Companies Act, 2013 read with the Companies (Indian Accounting Standards) Rules, 2015 (as amended).
5. The figures of the previous year/periods have been re-grouped/re-classified, wherever necessary, for the purpose of comparison with the current year/period figures.
6. The figures of the current quarter ended 31st March, 2022 and the quarter ended 31st March, 2020 are the balancing figures between the audited figures in respect of the full financial year ended respectively and published unaudited year to date figures upto the third quarter of the respective financial years.
7. The Company had no business operations during the quarter ending 31st March, 2022. Hence, segmentwise reprot as per Ind AS -108, is not applicable.
8. As per the orders dated 7th February, 2022, issued by NCLT, Hyderabad, the above Financial Results are prepared to meet the statutory requirements laid down by SEBI.
9. The above Financial Results are also available on the company's website www.bandaram.com

For and on Behalf of the Board of Directors
Bandaram Pharma Packtech Limited

(Formerly known as Shiva Medicare Limited)
For BANDARAM PHARMA PACKTECH LIMITED


B. Munirathnam Reddy
Managing Director
DIN: 09487708

Managing Director

Place : Bangalore
Date : 30.05.2022

For BANDARAM PHARMA PACKTECH LIMITED

Managing Director

BANDARAM PHARMA PACKTECH LIMITED (Formerly Known as Shiva Medicare Limited)

CIN: L93090KA1993PLC159827

Regd Office: 601,5th Floor, Oxford Towers, Opp. to Leela Palace Hotel, Old Airport Road, Kodihalli, Bangalore - 560008

Statement of Financial Position as at March 31, 2022 (Amount in lakhs)

	Particulars	As at March 31, 2022	As at Mar 31, 2021
I	ASSETS		
1	Non-current assets		
	(a) Property, plant and equipment	-	14.60
	(b) Right to use assets	-	-
	(c) Capital work in progress	-	-
	(d) Financial assets	-	-
	(i) Investments	-	-
	(ii) Trade receivables	-	-
	(iii) Loans & Advances	-	39.00
	(vi) other Financial assets	-	-
	(e) Deferred Tax Asset (Net)	-	-
	(f) Other non-current asset	91.66	-
	Total non-current assets (A)	91.66	53.60
2	Current assets		
	(a) Inventories	-	-
	(a) Financial assets	-	-
	(i) Investments	-	-
	(ii) Trade receivables	-	-
	(iii) Cash and cash equivalents	208.33	0.33
	(iv) Bank Balances other than (iii) above	-	-
	(v) Loans & Advances	-	76.51
	(iv) other financial assets	-	-
	(b) Current Tax Asset (Net)	-	-
	(c) Other current assets	-	0.83
	Total current assets (B)	208.33	77.67
	Non Current Assets Clasified as Held for Sale(C)		
	Total assets (A+B+C)	299.99	131.27
II	EQUITY AND LIABILITIES		
1	Equity		
	(a) Equity share capital	300.00	227.70
	(b) Other equity	(1.01)	(483.70)
	Total equity (A)	298.99	(256.00)
2	Liabilities		
(i)	Non-current liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	-	120.42
	(ii) Trade Payables	-	-
	(iii) Other Financial Liabilities	-	96.75
	(b) Long term provisions	-	-
	(c) Deferred tax Liabilities(Net)	-	-
	(d) Other non Current Liabilities	-	-
	Total non-current liabilities (B)	-	217.17
(ii)	Current liabilities		
	(a) Financial liabilities		
	(i) Borrowings	-	-
	(ii) Trade payables	-	-
	(iii) Other financial liabilities	-	-
	(b) Short term provisions	-	-
	(c) Other current liabilities	1.00	170.10
	(d) Current Tax Laibilities (net)	-	-
	Total current liabilities (C)	1.00	170.10
	Total equity and liabilities (A+B+C)	299.99	131.27

The notes are an integral part of the financial statements

For and on the Behalf of the Board of Directors

BANDARAM PHARMA PACKTECH LIMITED

For BANDARAM PHARMA PACKTECH LIMITED

B. Myniratnam Reddy
Managing Director

Managing Director

Place : Bangalore

Date : 30.05.2022

As per the Hon'ble NCLT Order dated: 07-02-2022, all the assets and liabilities are restated and accordingly adjusted in the books of accounts as per Approved Resolution Plan. The previous year figures are not comparables on account of CIRP Process.

Bandaram Pharma Packtech Limited

(Formerly Known as Shiva Medicare Limited)

CIN: L93090KA1993PLC159827


Regd Office: 601,5th Floor, Oxford Towers, Opp. to Leela Palace Hotel, Old Airport Road, Kodihalli, Bangalore - 560008

CASH FLOW STATEMENT (Amount in Lakhs)

Particulars	As at March 31, 2022	As at March 31, 2021
Net loss for the period before tax and extraordinary items	-1.01	-
Adjustments for:		
Depreciation	-	-
Interest Income	-	-
Interest expense	0.01	-
Increase in current liabilities	-169.10	-
(Increase) / Decrease in Loans, advances & Other	39.00	-
CIRP	-91.65	-
Decrease in Current Assets	77.34	-
Net Cash used in Operating Activities	-145.41	-
CASH FLOWS FROM INVESTING ACTIVITIES		
Payment towards acquisition of fixed assets	14.60	-
Proceeds / (Repayment) of Loans & advances	-72.96	-
Proceeds from long term liabilities	-144.22	-
Interest received	-	-
Net Cash provided by Investing Activities	-202.58	-
CASH FLOWS FROM FINANCING ACTIVITIES		
Issue of equity shares	293.78	-
Write-off debit balance in Profit and Loss Account	262.21	-
Net Cash provided / used by Financing Activities	555.99	-
Net Increase / (Decrease) in Cash & Cash equivalents - (a)	208.00	-
Opening cash & cash equivalents - (b)	0.33	0.33
Closing cash & cash equivalents - (a) + (b)	208.33	0.33

For and on the Behalf of the Board of Directors
BANDARAM PHARMA PACKTECH LIMITED
(Formerly Known as Shiva Medicare Limited)

For BANDARAM PHARMA PACKTECH LIMITED


B. Muralidhar Reddy
Managing Director
DIN: 09487708

Place : Bangalore
Date : 30.05.2022

As per the Hon'ble NCLT Order dated: 07-02-2022, all the assets and liabilities are restated and accordingly adjusted in the books of accounts as per Approved Resolution Plan. The previous year figures are not comparables on account of CIRP Process.



Independent Auditor's Report on Quarterly Standalone Financial Results and Year to Date pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015

To the Board of Directors of BANDARAM PHARMA PACKTECH LIMITED (Formerly Known as Shiva Medicare Limited)

Report on the Audit of Standalone Financial Results

Opinion

We have audited the accompanying standalone annual financial results of **BANDARAM PHARMA PACKTECH LIMITED (Formerly Known as Shiva Medicare Limited)** hereinafter referred to as 'the Company' for the quarter and year ended March 31, 2022 ('the Statement'), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Statement:

- i. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii. give a true and fair view in conformity with the applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with Companies (Indian Accounting Standards) Rules, 2015, as amended, and other accounting principles generally accepted in India, of net loss and other comprehensive income and other financial information of the company for the year ended March 31, 2022.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics.

We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

Board of Directors' Responsibilities for the Standalone Financial Results

This Statement have been prepared on the basis of the standalone annual financial statements. The Company's Board of Directors are responsible for the preparation and presentation of this Statement that give a true and fair view of the net loss and other



comprehensive income in accordance with the Indian Accounting Standards prescribed under Section 133 of the Act read with Companies (Indian Accounting Standards) Rules, 2015, as amended issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Board of Directors of the Company are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Statement by the Directors of the Company, as aforesaid.

In preparing the Statement, the Board of Directors of the Company are responsible for assessing the ability of the Company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors of the Company are responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors use of the going concern



basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance of the Company of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.


Other Matters:

As per the orders dated 7th February, 2022, issued by NCLT, Hyderabad, on approval of the Resolution Plan, the above Financial Results are prepared to meet the statutory requirements laid down by SEBI.

The statement does not includes the results for the previous quarters the companies financials are prepared by the new management based on the approved resolution plan for the quarter and not reported the previous period figures as the same is not available with the management and same prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" which were subject to limited review by us.

Our opinion is not modified in respect of the above matters.

For M M REDDY & CO.,
Chartered Accountants
Firm Registration No.010371S


M. Madhusudhana Reddy
Partner
Membership No.234165
UDIN: 22213077AJWAKA8253



Date: 30.05.2022
Place: Hyderabad

BANDARAM PHARMA PACKTECH LIMITED

(Formerly known as Shiva Medicare Limited)

CIN: L93090KA1993PLC159827

Date: 30.05.2022

To,
BSE Limited
P.J. Towers, Dalal Street,
Mumbai: 400001

Dear Sir/Madam,

Sub: Declaration pursuant to regulation 33 (3) (d) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

I, B. Munirathnam Reddy, Managing Director of Bandaram Pharma Packtech Limited (formerly known as Shiva Medicare Limited) hereby declare that, the statutory Auditors of the company, M/s M. M. Reddy & CO., Chartered Accountants have issued an Audit Report with unmodified/unqualified opinion on Standalone and Consolidated Audited Financial Results of the company for the quarter and year ended 31st March, 2022.

This declaration is issued in compliance of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you.

Yours sincerely,
For Bandaram Pharma Packtech Limited
(Formerly known as Shiva Medicare Limited)



B. Munirathnam Reddy
Managing Director
DIN: 09487708